Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.5500 |
Strike | 5.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.0500 - 0.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 150 |
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
BRISBANE, Calif., May 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of common
BRISBANE, Calif., April 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.